UBS AM’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.72K Buy
+736
New +$6.17K ﹤0.01% 3396
2025
Q3
Sell
-144,435
Closed -$956K 2336
2025
Q2
$956K Buy
144,435
+64,936
+82% +$460K ﹤0.01% 2395
2025
Q1
$727K Buy
79,499
+14,344
+22% +$143K ﹤0.01% 2418
2024
Q4
$684K Buy
+65,155
New +$771K ﹤0.01% 2489
2023
Q1
Sell
-55,511
Closed -$145K 2682
2022
Q4
$145K Buy
+55,511
New +$242K ﹤0.01% 2476
2021
Q4
Sell
-388,533
Closed -$5.5M 2853
2021
Q3
$5.5M Sell
388,533
-11,295
-3% -$174K ﹤0.01% 1314
2021
Q2
$7.04M Buy
+399,828
New +$6.44M ﹤0.01% 1238

Other funds holding BVS

UBS AM's BVS Position: Q1 2026 in Review

UBS AM opened a new position in Bioventus (BVS) in Q1 2026: 736 shares worth $6.72K. The stake represents ﹤0.01% of the portfolio and ranks #3396 among its holdings. This is a return to the name: UBS AM previously reported a position in BVS as recently as Q2 2025.

UBS AM first reported a position in BVS in Q2 2021 and has held it in 7 quarters since. The position peaked at $7.04M in Q2 2021. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • UBS AM held 736 shares of Bioventus worth $6.72K as of Q1 2026.
  • Bioventus was a new UBS AM position in Q1 2026.
  • Bioventus made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3396 holding.
  • UBS AM first reported a position in Bioventus in Q2 2021 and has held it in 7 quarters since.
  • UBS AM's Bioventus position peaked at $7.04M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.